Literature DB >> 22848270

Trisomy chromosome 5 is a recurrent cytogenetic lesion in mammary tumors from parous MMTV-erbB-2 transgenic mice.

Young Mi Kim1, Zhikun Ma, Seungjik Lee, Jiyun Lee, Shibo Li, Xiaohe Yang.   

Abstract

erbB-2 is amplified or overexpressed in approximately 30% of human breast cancers, and has been associated with poor prognosis and therapeutic resistance. Previous studies have suggested that erbB-2 overexpression in transgenic mice induces genomic instability; however, the patterns of genetic lesions vary with individual model systems. The development of mammary tumors in multiparous murine mammary tumor virus (MMTV)-erbB-2 transgenic mice is accelerated due to hormonal interactions which induce the overexpression of MMTV-mediated erbB-2. However, whether or not accelerated tumor development is associated with modified cytogenetic patterns remains to be determined. In this study, chromosomal changes were characterized in mammary tumor cells derived from multiparous MMTV-erbB-2 transgenic mice, and compared with tumor cells derived from control virgin mice. Immunohistochemistry and Western blotting were used to detect erbB-2 overexpression in mammary tissues. Each of the five tumors from the multiparous MMTV-erbB-2 transgenic mice was found to exhibit a marked chromosomal imbalance, compared with only one tumor with aberrant chromosomes among the five tumors from the control virgin mice. In particular, trisomy 5 and loss of the X chromosome were recurrent cytogenetic lesions in tumors from the parous mice, which is a novel pattern compared with previous studies. The elevated number of genetic lesions in tumors from parous mice, which were characterized by enhanced erbB-2 overexpression and increased receptor tyrosine kinase activation in the mammary glands, suggest a causal role for erbB-2 in the genomic instability present in these tumors. These data advance our understanding of erbB-2-mediated pathogenesis and underscore the role of cytogenetic alteration in this process.

Entities:  

Year:  2011        PMID: 22848270      PMCID: PMC3406573          DOI: 10.3892/ol.2011.373

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  16 in total

Review 1.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.

Authors:  N Prenzel; O M Fischer; S Streit; S Hart; A Ullrich
Journal:  Endocr Relat Cancer       Date:  2001-03       Impact factor: 5.678

2.  Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu.

Authors:  Cristina Montagna; Eran R Andrechek; Hesed Padilla-Nash; William J Muller; Thomas Ried
Journal:  Oncogene       Date:  2002-01-31       Impact factor: 9.867

3.  Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer.

Authors:  P M Siegel; E D Ryan; R D Cardiff; W J Muller
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

4.  neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice.

Authors:  B Li; J M Rosen; J McMenamin-Balano; W J Muller; A S Perkins
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

5.  Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling.

Authors:  J Graeme Hodgson; Tiffany Malek; Sophia Bornstein; Sujatmi Hariono; David G Ginzinger; William J Muller; Joe W Gray
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors:  A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

8.  Number of pregnancies and ovariectomy modify mammary carcinoma development in transgenic HER-2/neu female mice.

Authors:  Vladimir N Anisimov; Irina G Popovich; Irina N Alimova; Mark A Zabezhinski; Anna V Semenchenko; Anatoli I Yashin
Journal:  Cancer Lett       Date:  2003-04-10       Impact factor: 8.679

9.  Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.

Authors:  Aeree Kim; Bolin Liu; Dalia Ordonez-Ercan; Kathy M Alvarez; Lynn D Jones; Christine McKimmey; Susan M Edgerton; Xiaohe Yang; Ann D Thor
Journal:  Breast Cancer Res       Date:  2005-07-06       Impact factor: 6.466

Review 10.  Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases.

Authors:  D F Stern
Journal:  Breast Cancer Res       Date:  2000-03-25       Impact factor: 6.466

View more
  1 in total

1.  DMBA promotes ErbB2‑mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability.

Authors:  Zhikun Ma; Young Mi Kim; Erin W Howard; Xiaoshan Feng; Stanley D Kosanke; Shihe Yang; Yunbo Jiang; Amanda B Parris; Xia Cao; Shibo Li; Xiaohe Yang
Journal:  Oncol Rep       Date:  2018-07-04       Impact factor: 3.906

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.